Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Rubino

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Clinical Pharmacokinetics|August 17, 2022
Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis BronchiectasisJames D Chalmers, Helen Usansky, Christopher M Rubino, et al.
Journal of Clinical Pharmacology|December 2, 2017
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose SelectionDavid J Greenblatt, Maulik Patel, Jerold S Harmatz, et al.
Antimicrobial Agents and Chemotherapy|January 10, 2018
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal ImpairmentChristopher M Rubino, Sujata M Bhavnani, Jeffery S Loutit, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2006
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymorePaul G Ambrose, Sujata M Bhavnani, Christopher M Rubino, et al.
Antimicrobial Agents and Chemotherapy|April 14, 2025
Population pharmacokinetic analysis of tobramycin in serum and ELF using data from patients with pneumoniaScott A Van Wart, Michael Trang, M Courtney Safir, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2009
Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremiaChristopher M Rubino, Scott A Van Wart, Sujata M Bhavnani, et al.
Journal of Clinical Pharmacology|November 17, 2020
Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric PatientsMichael L Schmitz, Christopher M Rubino, Nikolas J Onufrak, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2019
Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation SolutionElizabeth A Lakota, Nobuo Sato, Tomokazu Koresawa, et al.
Antimicrobial Agents and Chemotherapy|October 6, 2010
Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumoniaChristopher M Rubino, Alan Forrest, Sujata M Bhavnani, et al.
Open Forum Infectious Diseases|December 25, 2018
Time for Precision: A World Without Susceptibility BreakpointsJustin C Bader, Elizabeth A Lakota, David R Andes, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Clinical Pharmacokinetics|August 17, 2022
Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis BronchiectasisJames D Chalmers, Helen Usansky, Christopher M Rubino, et al.
Journal of Clinical Pharmacology|December 2, 2017
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose SelectionDavid J Greenblatt, Maulik Patel, Jerold S Harmatz, et al.
Antimicrobial Agents and Chemotherapy|January 10, 2018
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal ImpairmentChristopher M Rubino, Sujata M Bhavnani, Jeffery S Loutit, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2006
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymorePaul G Ambrose, Sujata M Bhavnani, Christopher M Rubino, et al.
Antimicrobial Agents and Chemotherapy|April 14, 2025
Population pharmacokinetic analysis of tobramycin in serum and ELF using data from patients with pneumoniaScott A Van Wart, Michael Trang, M Courtney Safir, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2009
Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremiaChristopher M Rubino, Scott A Van Wart, Sujata M Bhavnani, et al.
Journal of Clinical Pharmacology|November 17, 2020
Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric PatientsMichael L Schmitz, Christopher M Rubino, Nikolas J Onufrak, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2019
Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation SolutionElizabeth A Lakota, Nobuo Sato, Tomokazu Koresawa, et al.
Antimicrobial Agents and Chemotherapy|October 6, 2010
Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumoniaChristopher M Rubino, Alan Forrest, Sujata M Bhavnani, et al.
Open Forum Infectious Diseases|December 25, 2018
Time for Precision: A World Without Susceptibility BreakpointsJustin C Bader, Elizabeth A Lakota, David R Andes, et al.
Pageof 7